Understanding VNS Therapy Complications: What Every Patient and Provider Should Know
VNS therapy complications affect approximately 11-25% of patients who undergo vagus nerve stimulation, making it essential to understand both the common and rare side effects before treatment begins.
Quick Overview of VNS Therapy Complications:
- Early complications (0-30 days): Infection (2.6%), vocal cord palsy (1.4%), postoperative hematoma (1.9%)
- Hardware issues: Lead fracture (3.0%), device malfunction (0.2%), generator problems
- Chronic side effects: Hoarseness (27.4%), cough (13.3%), shortness of breath (9.9%)
- Serious but rare: Cardiac effects (1.8%), sleep apnea (5.5%), SUDEP risk changes
VNS therapy offers hope for patients with drug-resistant epilepsy and treatment-resistant depression, but like any medical intervention, it comes with risks that need careful consideration. Research shows that while most complications are minor and manageable, some can be serious enough to require device adjustment or removal in about 5.5% of cases.
Understanding these complications helps patients make informed decisions and healthcare providers deliver better care. The key is balancing the potential benefits of seizure reduction and mood improvement against the realistic possibility of side effects – many of which diminish over time or can be managed through device programming adjustments.
I’m Dr. Erika Peterson, I’ve spent years studying neuromodulation devices and their complications in my role as Director of Functional and Restorative Neurosurgery at UAMS Medical Center. My research focuses on developing safer approaches to VNS therapy complications and helping patients steer the complex decisions around implantable devices.
Early Complications: What Happens During and After Surgery?
The first few weeks after VNS implantation are crucial, as this is when most VNS therapy complications related to the procedure are likely to appear.
VNS surgery involves two small incisions: one in the upper left chest for the pulse generator and another in the neck to connect a thin wire to the vagus nerve. While generally straightforward, any implant surgery has risks.
Research shows that surgical complications happen in about 8.6% of VNS procedures, while hardware issues occur in roughly 3.7% of cases. Most of these are minor, and your surgical team waits at least two weeks before turning on your device to allow for healing.
Surgical & Post-Operative Issues
Here’s what might happen in the initial weeks as your body adjusts.
Infection is a primary concern, occurring in about 2.6% of VNS procedures despite sterile techniques and antibiotics. Children with intellectual disabilities have a slightly higher rate (3.4%), possibly due to wound care challenges.
Postoperative bleeding (hematoma) occurs in about 1.9% of procedures. Most are absorbed naturally, but larger collections may need draining.
Voice changes can happen if the VNS lead irritates the vocal cord branch of the vagus nerve (1.4% chance). Most voice changes are temporary but can be unsettling when they first appear.
Nerve damage beyond voice issues is rare. However, surgical trauma or a broken lead can compress the vagus nerve, leading to voice weakness or seizure breakthrough, emphasizing the need for surgical precision.
Wound healing problems affect about 1.4% of patients, causing discomfort, pain, or numbness around incision sites. These issues usually improve with time and proper wound care.
Permanent complications from VNS surgery are rare, happening in only about 0.5% of cases.
Hardware-Related Problems
Even sophisticated technology can have mechanical issues. These problems relate to the physical components rather than the body’s response.
Lead fractures are the most common hardware issue (3.0% overall). The wire connecting the generator to the nerve can break, especially in active children. Pediatric patients experience lead breakage in 11.3% of cases versus 3.1% in adults.
When a lead breaks, stimulation stops, potentially causing seizure recurrence or new symptoms like voice changes until it is repaired.
Device migration, where the generator or leads shift, occurs in about 1.7% of procedures, more commonly in pediatric patients with intellectual disabilities.
Generator failure is uncommon. Most last 5-6 years, but some fail prematurely. Battery replacement surgery has its own small complication risk of about 2.5%.
Patient manipulation (“Twiddler’s Syndrome”) occurs when patients fidget with their generator, which can cause migration, lead fracture, or skin erosion. Patient education helps prevent this.
The key with hardware problems is early detection. Contact your healthcare team if you notice new symptoms or device issues. Quick action can prevent minor issues from becoming major problems.
Long-Term VNS Therapy Complications and Side Effects
Once the surgical sites heal, you enter the “chronic phase” of therapy, where the device delivers regular stimulation (e.g., on for 30 seconds, off for 5 minutes). During this phase, VNS therapy complications are typically related to the ongoing electrical stimulation as your body adjusts.
Most side effects from chronic stimulation are manageable and often improve over time. By adjusting device settings—tweaking the intensity, frequency, or timing of pulses—we can often find a “Goldilocks zone” of maximum benefit with minimal discomfort.
Common Stimulation-Related Side Effects
These side effects occur because the vagus nerve carries signals to many destinations, including the voice box and breathing pathways.
Hoarseness is the most common side effect. Stimulation of the vagus nerve can affect the vocal cords, causing a raspy or weak voice during the device’s “on” cycles. It affects 4.3% to 27.4% of patients, depending on device settings and individual sensitivity.
Chronic cough can develop in 2.6% to 13.3% of patients, often described as a tickle in the throat that coincides with stimulation.
Dyspnea, or shortness of breath, may occur during stimulation. This feeling of throat tightness is usually mild and temporary, affecting 2.6% to 9.9% of patients.
Dysphagia (difficulty swallowing) can occur in 1.5% to 2.6% of patients. Using the handheld magnet to pause stimulation during meals can help.
Paresthesia (tingling or numb sensations) is felt by about 10.2% of patients, typically in the neck, head, or face.
Neck pain, muscle pain (6.2%), or headaches (10.1%) can also coincide with stimulation periods.
Fortunately, we can adjust the output current and other settings to minimize these effects. We start with low settings and increase them gradually, allowing the body to adapt. Many side effects that are bothersome initially become less noticeable over time.
Less Common but Serious VNS Therapy Complications
While most complications are manageable, some less common but more serious effects require careful attention.
Cardiac effects are a key concern. Although implanting on the left vagus nerve minimizes risk, atrioventricular (AV) block—a heart rhythm disruption—occurs in about 1.8% of patients. This can cause a slow heart rate (bradycardia) or, rarely, a temporary stop in heart activity during testing. We monitor patients closely, especially those on certain seizure medications, and may recommend a pacemaker if severe rhythm problems develop.
Sleep-related breathing disorders are another serious concern. About 5.5% of patients develop obstructive sleep apnea (OSA), which appears to be dose-dependent. Since stimulation can affect airway muscles, it may worsen breathing during sleep. Treatments like CPAP therapy may be necessary.
Laryngeal issues can go beyond hoarseness to more persistent problems like ongoing vocal cord dysfunction in about 3.6% of patients.
Rare presentations can also occur. One study found that 4.3% of patients experienced unusual complications years after implantation, such as rhythmic tremors, dystonic pulling sensations, or voice problems from a compressed or broken lead. Early recognition is key.
For healthcare providers wanting to dive deeper into these long-term insights, Complications and safety of vagus nerve stimulation: 25 years of experience at a single center provides valuable perspective from decades of clinical experience.
VNS and Specific Health Concerns
Certain pre-existing medical conditions can make VNS therapy complications more likely or serious. For example, patients with heart or breathing problems require extra careful planning, as the vagus nerve influences these systems. Understanding these interactions allows for a safer, more personalized treatment approach with closer monitoring.
Impact on Cardiac Health
The vagus nerve acts as a natural brake for your heart rate, so we pay close attention to cardiac health.
Bradycardia and atrioventricular (AV) block are serious cardiac concerns. Despite implanting on the left vagus nerve to minimize heart effects, severe AV block occurred in 1.8% of patients in our studies, sometimes years after surgery. The situation can be trickier for patients taking medications that also affect heart rhythm.
Asystole (temporary heart stoppage) is extremely rare but is our most serious concern. It can occur when the device is first tested, which is why full cardiac monitoring is used during surgery.
If you have pre-existing heart conditions, a thorough cardiac evaluation is necessary before considering VNS.
Management strategies start with adjusting VNS settings. For severe symptoms, a pacemaker may be implanted to stabilize heart rhythm while allowing VNS therapy to continue. Periodic EKGs are also recommended for some patients.
VNS Therapy, Sleep Apnea, and SUDEP
Sleep problems and epilepsy often coexist, and VNS can sometimes complicate this relationship by affecting airway muscles during sleep.
Obstructive Sleep Apnea (OSA) develops in about 5.5% of patients after starting VNS therapy, often in a dose-dependent manner. Higher stimulation settings may increase the risk. A sleep study (polysomnography) can confirm a diagnosis.
Managing VNS-related sleep apnea involves balancing treatments. Options include adjusting VNS settings, recommending CPAP therapy, or, in some cases, surgical options like uvulopalatopharyngoplasty (UPPP).
Sudden Unexpected Death in Epilepsy (SUDEP) is a major concern for those with epilepsy. The relationship with VNS is complex, but the SUDEP rate in VNS patients is about 3.4 per 1,000 person-years. Some research suggests VNS may reduce SUDEP risk over time by improving seizure control. However, VNS does not eliminate all seizures. The potential for SUDEP risk reduction is an important factor when weighing the benefits and risks of therapy.
Managing and Mitigating Risks
We actively work to prevent VNS therapy complications through careful patient selection, meticulous surgical technique, and a strong patient-provider partnership. It’s not about avoiding all risks, but managing them intelligently based on what we’ve learned from thousands of patients.
Identifying High-Risk Patient Populations
Recognizing that not every patient faces the same risk profile helps us provide better, more personalized care.
Pediatric patients, especially those aged 4-11, have higher rates of infection and lead breakage (11.3% vs. 3.1% in adults). This is due to their active lifestyles, growth, and smaller anatomy, requiring extra care.
Individuals with intellectual disability also require special consideration. They show higher rates of infection, lead breakage, and device migration, often due to factors like less controlled movements or device manipulation. This requires modified approaches, including detailed caregiver education and closer monitoring.
Pre-existing cardiac conditions demand a thorough cardiac assessment before implantation, as the vagus nerve directly influences heart rhythm.
Pre-existing sleep apnea is another concern, as VNS can potentially worsen breathing issues during sleep. Sleep studies may be recommended before implantation.
Anatomical variations around the vagus nerve are rare but can increase surgical complexity. Advanced imaging helps identify these situations beforehand.
For those interested in how we study these risk factors in real-world settings, you can Explore Mayo Clinic studies on VNS therapy to see ongoing research efforts.
Prevention and Management Strategies
Comprehensive strategies have been developed to minimize VNS therapy complications.
Surgical technique is foundational. Strict sterile conditions, prophylactic antibiotics, and precise lead placement on the main vagus nerve trunk help minimize complications, especially cardiac-related ones.
Device settings adjustment is a powerful tool. Since many side effects are dose-dependent, we can often resolve them by fine-tuning the device. We start with low settings and increase them gradually, allowing the body to adapt.
Patient education empowers individuals to participate in their care. We teach patients how to use the VNS magnet to temporarily stop stimulation for immediate relief from side effects like coughing or difficulty swallowing.
Regular follow-ups allow for early detection and intervention, ensuring that emerging complications are caught when they are most manageable.
Magnet use gives patients immediate control. Swiping the magnet can provide extra stimulation during a seizure aura or temporarily stop stimulation to relieve side effects, significantly improving daily quality of life.
Device deactivation or removal is an option if complications are severe. Complete removal has a 27.3% complication rate, but partial removal has shown a 0% complication rate while still maintaining MRI compatibility. This decision is always made in a multidisciplinary setting.
Conclusion
I hope this guide helps you feel more prepared and confident about what to expect from VNS therapy.
The reality is that VNS therapy complications affect a minority of patients, and most are manageable. Side effects like hoarseness or a cough often become less bothersome as your body adjusts. Serious complications like cardiac effects or sleep apnea are rare, and we have established protocols to address them, often by simply adjusting device settings.
Encouragingly, we have learned a great deal about preventing complications over the past 25 years. Improved surgical techniques, patient selection, and device programming have led to safer outcomes.
The key to success with VNS therapy is the partnership between you and your healthcare team. Informed consent means truly understanding your treatment choice. Regular follow-ups and open communication are crucial for the best results.
At Neuromodulation, we’re committed to providing patients and providers with the latest, most accurate information. The field continues to evolve, with new technologies emerging that may further reduce complications.
Millions of people worldwide have benefited from VNS therapy. While no medical intervention is risk-free, the potential for reduced seizures, improved mood, and better quality of life often outweighs the manageable risks.
For those ready to explore the broader world of neuromodulation, I encourage you to learn more about our advanced neuromodulation resources. The future of these therapies looks bright as our understanding deepens.